Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 465

The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.

The Treatment of Cushing's Disease

Open access
Pivonello, Rosario, De Leo, Monica, Cozzolino, Alessia, Colao, Annamaria·2015·Endocrine Reviews
DOI 10.1210/er.2013-1048
Open this paper in CoChat — free account

Abstract

Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe endocrine disease caused by a corticotroph pituitary tumor and associated with increased morbidity and mortality. The first-line treatment for CD is pituitary surgery, which is followed by disease remission in around 78% and relapse in around 13% of patients during the 10-year period after surgery, so that nearly one third of patients experience in the long-term a failure of surgery and require an additional second-line treatment. Patients with persistent or recurrent CD require additional treatments, including pituitary radiotherapy, adrenal surgery, and/or medical therapy. Pituitary radiotherapy is effective in controlling cortisol excess in a large percentage of patients, but it is associated with a considerable risk of hypopituitarism. Adrenal surgery is followed by a rapid and definitive control of cortisol excess in nearly all patients, but it induces adrenal insufficiency. Medical therapy has recently acquired a more important role compared to the past, due to the recent employment of novel compounds able to control cortisol secretion or action. Currently, medical therapy is used as a presurgical treatment, particularly for severe disease; or as postsurgical treatment, in cases of failure or incomplete surgical tumor resection; or as bridging therapy before, during, and after radiotherapy while waiting for disease control; or, in selected cases, as primary therapy, mainly when surgery is not an option. The adrenal-directed drug ketoconazole is the most commonly used drug, mainly because of its rapid action, whereas the glucocorticoid receptor antagonist, mifepristone, is highly effective in controlling clinical comorbidities, mainly glucose intolerance, thus being a useful treatment for CD when it is associated with diabetes mellitus. Pituitary-directed drugs have the advantage of acting at the site responsible for CD, the pituitary tumor. Among this group of drugs, the dopamine agonist cabergoline and the somatostatin analog pasireotide result in disease remission in a consistent subgroup of patients with CD. Recently, pasireotide has been approved for the treatment of CD when surgery has failed or when surgery is not an option, and mifepristone has been approved for the treatment of Cushing's syndrome when associated with impairment of glucose metabolism in case of the lack of a surgical indication. Recent experience suggests that the combination of different drugs may be able to control cortisol excess in a great majority of patients with CD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2013-1048

Cites

641 of 641 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 641 references

Research works printed but not linked: 143

  1. Lüdecke, 1976, Selective removal of hypersecreting pituitary adenomas? An analysis of endocrine function, operative and microscopical findings in 101 cases, Acta Neurochir (Wien), 35, 27, 10.1007/BF01405930 · doi:10.1007/bf01405930
  2. Carmalt, 1977, The treatment of Cushing's disease by trans-sphenoidal hypophysectomy, Q J Med, 46, 119
  3. Wajchenberg, 1979, Evaluation of resection of pituitary microadenoma for the treatment of Cushing's disease in patients with radiologically normal sella turcica, Clin Endocrinol (Oxf), 11, 323, 10.1111/j.1365-2265.1979.tb03081.x · doi:10.1111/j.1365-2265.1979.tb03081.x
  4. Hardy, 1982, Presidential address: XVII Canadian Congress of Neurological Sciences. Cushing's disease: 50 years later, Can J Neurol Sci, 9, 375, 10.1017/S0317167100044279 · doi:10.1017/s0317167100044279
  5. Thomas, 1983, Long term results of radical hypophysectomy for Cushing's disease, Clin Endocrinol (Oxf), 19, 629, 10.1111/j.1365-2265.1983.tb00041.x · doi:10.1111/j.1365-2265.1983.tb00041.x
  6. Brand, 1985, Long-term follow up of trans-sphenoidal hypophysectomy for Cushing's disease, J R Soc Med, 78, 291, 10.1177/014107688507800404 · doi:10.1177/014107688507800404
  7. Tagliaferri, 1986, Transsphenoidal microsurgery for Cushing's disease, Acta Endocrinol (Copenh), 113, 5, 10.1530/acta.0.1130005 · doi:10.1530/acta.0.1130005
  8. van Aken, 1997, Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease, Clin Endocrinol (Oxf), 47, 145, 10.1046/j.1365-2265.1997.2541051.x · doi:10.1046/j.1365-2265.1997.2541051.x
  9. Vignati, 1994, Early postoperative evaluation in patients with Cushing's disease: usefulness of ovine corticotropin-releasing hormone test in the prediction of recurrence of disease, Eur J Endocrinol, 130, 235, 10.1530/eje.0.1300235 · doi:10.1530/eje.0.1300235
  10. Powell, 2009, Microscope and endoscopic pituitary surgery, Acta Neurochirurgica, 151, 723, 10.1007/s00701-009-0297-2 · doi:10.1007/s00701-009-0297-2
  11. Ciric, 2002, Transsphenoidal microsurgery, Neurosurgery, 51, 161, 10.1097/00006123-200207000-00023 · doi:10.1097/00006123-200207000-00023
  12. Ciric, 2006, Transsphenoidal microsurgery: past, present and future, Expert Rev Anticancer Ther, 6, S75, 10.1586/14737140.6.9s.S75 · doi:10.1586/14737140.6.9s.s75
  13. Cappabianca, 1998, Endoscopic endonasal transsphenoidal approach to the sella: towards functional endoscopic pituitary surgery (FEPS), Minim Invasive Neurosurg, 41, 66, 10.1055/s-2008-1052019 · doi:10.1055/s-2008-1052019
  14. Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
  15. Strychowsky, 2011, Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review, J Otolaryngol Head Neck Surg, 40, 175
  16. Laws, 2014, The transition from microscopic to endoscopic transsphenoidal surgery: the experience at Brigham and Women's Hospital, World Neurosurg, 82, S152, 10.1016/j.wneu.2014.07.035 · doi:10.1016/j.wneu.2014.07.035
  17. Haddad, 1991, Pediatric pituitary tumors, Neurosurgery, 29, 509, 10.1227/00006123-199110000-00004 · doi:10.1227/00006123-199110000-00004
  18. Mehrazin, 2007, Pituitary tumors in children: clinical analysis of 21 cases, Childs Nerv Syst, 23, 391, 10.1007/s00381-006-0259-4 · doi:10.1007/s00381-006-0259-4
  19. Doniach, 1977, Histopathology of the anterior pituitary, Clin Endocrinol Metab, 6, 21, 10.1016/S0300-595X(77)80055-8 · doi:10.1016/s0300-595x(77)80055-8
  20. Kovács, 2013, ACTH-secreting Crooke cell carcinoma of the pituitary, Eur J Clin Invest, 43, 20, 10.1111/eci.12010 · doi:10.1111/eci.12010
  21. Felix, 1981, Massive Crooke's hyalinization in corticotroph cell adenomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases, Acta Neurochir (Wien), 58, 235, 10.1007/BF01407130 · doi:10.1007/bf01407130
  22. Jho, 1996, Endoscopy assisted transsphenoidal surgery for pituitary adenoma. Technical note, Acta Neurochir (Wien), 138, 1416, 10.1007/BF01411120 · doi:10.1007/bf01411120
  23. Cappabianca, 2002, Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas, J Neurosurg, 97, 293, 10.3171/jns.2002.97.2.0293 · doi:10.3171/jns.2002.97.2.0293
  24. Zada, 2010, Intraoperative conversion from endoscopic to microscopic approach for the management of sellar pathology: incidence and rationale in a contemporary series, World Neurosurg, 73, 334, 10.1016/j.wneu.2010.02.069 · doi:10.1016/j.wneu.2010.02.069
  25. Murty, 1990, Early inappropriate secretion of antidiuretic hormone after trans-sphenoidal pituitary adenomectomy, J Laryngol Otol, 104, 894, 10.1017/S0022215100114288 · doi:10.1017/s0022215100114288
  26. Ultmann, 1992, Transient hyponatremia after damage to the neurohypophyseal tracts, Neuroendocrinology, 56, 803, 10.1159/000126310 · doi:10.1159/000126310
  27. Levy, 1991, Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients, Stereotact Funct Neurosurg, 57, 22, 10.1159/000099553 · doi:10.1159/000099553
  28. Edmonds, 1972, External irradiation of the hypophysis for Cushing's disease, Can Med Assoc J, 107, 860
  29. Ahmed, 1984, Treatment of Cushing's disease with low dose radiation therapy, Br Med J Clin Res Ed, 289, 643, 10.1136/bmj.289.6446.643 · doi:10.1136/bmj.289.6446.643
  30. Vicente, 1991, Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease, Acta Endocrinol (Copenh), 125, 470, 10.1530/acta.0.1250470 · doi:10.1530/acta.0.1250470
  31. Grigsby, 1988, Long-term results of radiotherapy in the treatment of pituitary adenomas in children and adolescents, Am J Clin Oncol, 11, 607, 10.1097/00000421-198812000-00001 · doi:10.1097/00000421-198812000-00001
  32. Degerblad, 1986, Long-term results of stereotactic radiosurgery to the pituitary gland in Cushing's disease, Acta Endocrinol (Copenh), 112, 310, 10.1530/acta.0.1120310 · doi:10.1530/acta.0.1120310
  33. Ganz, 1993, The effects of Gamma Knife surgery of pituitary adenomas on tumor growth and endocrinopathies. Stereotact, Funct Neurosurg, 61, 30, 10.1159/000100657 · doi:10.1159/000100657
  34. Inoue, 1999, Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: experience in 122 cases, Stereotact Funct Neurosurg, 72, 125, 10.1159/000056448 · doi:10.1159/000056448
  35. Mokry, 1999, A six year experience with the postoperative radiosurgical management of pituitary adenomas, Stereotact Funct Neurosurg, 72, 88, 10.1159/000056444 · doi:10.1159/000056444
  36. Shin, 2000, Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus, J Neurosurg, 93, 2, 10.3171/jns.2000.93.supplement_3.0002 · doi:10.3171/jns.2000.93.supplement_3.0002
  37. Kobayashi, 2002, Gamma knife radiosurgery in the treatment of Cushing disease: long-term results, J Neurosurg, 97, 422, 10.3171/jns.2002.97.supplement_5.0422 · doi:10.3171/jns.2002.97.supplement_5.0422
  38. Wong, 2003, LINAC radiosurgery in recurrent Cushing's disease after transsphenoidal surgery: a series of 5 cases, Minim Invasive Neurosurg, 46, 327, 10.1055/s-2003-812497 · doi:10.1055/s-2003-812497
  39. Choi, 2003, Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery, Yonsei Med J, 44, 602, 10.3349/ymj.2003.44.4.602 · doi:10.3349/ymj.2003.44.4.602
  40. Kajiwara, 2005, Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas, Minim Invasive Neurosurg, 48, 91, 10.1055/s-2004-830261 · doi:10.1055/s-2004-830261
  41. Zeiler, 2013, Gamma knife in the treatment of pituitary adenomas: results of a single center, Can J Neurol Sci, 40, 546, 10.1017/S0317167100014645 · doi:10.1017/s0317167100014645
  42. Kim, 1999, Gamma Knife radiosurgery for functioning pituitary microadenoma, Stereotact Funct Neurosurg, 72, 119, 10.1159/000056447 · doi:10.1159/000056447
  43. Landolt, 2000, Gamma knife radiosurgery for prolactinomas, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
  44. Aristizabal, 1977, Relationship of time dose factors to tumor control and complications in the treatment of Cushing's disease by irradiation, Int J Radiat Oncol Biol Phys, 2, 47, 10.1016/0360-3016(77)90007-4 · doi:10.1016/0360-3016(77)90007-4
  45. Chen, 2001, Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications, Neurosurgery, 48, 1022
  46. Ove, 2000, Preservation of visual fields after peri-sellar gamma-knife radiosurgery, Int J Cancer, 90, 343, 10.1002/1097-0215(20001220)90:6<343::AID-IJC6>3.0.CO;2-H · doi:10.1002/1097-0215(20001220)90:6<343::aid-ijc6>3.0.co;2-h
  47. Mehta, 1993, Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?, Int J Radiat Oncol Biol Phys, 27, 477, 10.1016/0360-3016(93)90262-T · doi:10.1016/0360-3016(93)90262-t
  48. Liu, 2005, Gamma knife radiosurgery for tumors involving the cavernous sinus, Stereotact Funct Neurosurg, 83, 45, 10.1159/000085544 · doi:10.1159/000085544
  49. Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
  50. Lundström, 1976, Atrophy of optic nerve fibres in compression of the chiasm. Degree and distribution of ophthalmoscopic changes, Acta Ophthalmol (Copenh), 54, 623, 10.1111/j.1755-3768.1976.tb01291.x · doi:10.1111/j.1755-3768.1976.tb01291.x
  51. Abe, 2002, Early palliation of oculomotor nerve palsy following gamma knife radiosurgery for pituitary adenoma, Eur Neurol, 47, 61, 10.1159/000047951 · doi:10.1159/000047951
  52. Packer, 2002, Radiation-induced neurocognitive decline: the risks and benefits of reducing the amount of whole-brain irradiation, Curr Neurol Neurosci Rep, 2, 131, 10.1007/s11910-002-0021-6 · doi:10.1007/s11910-002-0021-6
  53. Guinan, 1998, Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients, J Neurol Neurosurg Psychiatry, 65, 870, 10.1136/jnnp.65.6.870 · doi:10.1136/jnnp.65.6.870
  54. Niranjan, 2009, Neoplastic transformation after radiosurgery or radiotherapy: risk and realities, Otolaryngol Clin North Am, 42, 717, 10.1016/j.otc.2009.04.005 · doi:10.1016/j.otc.2009.04.005
  55. Jones, 1991, Radiation oncogenesis in relation to the treatment of pituitary tumours, Clin Endocrinol (Oxf), 35, 379, 10.1111/j.1365-2265.1991.tb03554.x · doi:10.1111/j.1365-2265.1991.tb03554.x
  56. Wu-Chen, 2009, Intracranial malignancies occurring more than 20 years after radiation therapy for pituitary adenoma, J Neuroophthalmol, 29, 289, 10.1097/WNO.0b013e3181b4a1be · doi:10.1097/wno.0b013e3181b4a1be
  57. Ecemis, 2013, Radiation-associated secondary brain tumors after conventional radiotherapy and radiosurgery, Expert Rev Neurother, 13, 557, 10.1586/ern.13.37 · doi:10.1586/ern.13.37
  58. Tsukamoto, 1992, Meningioma developed 25 years after radiation therapy for Cushing's disease, Intern Med, 31, 629, 10.2169/internalmedicine.31.629 · doi:10.2169/internalmedicine.31.629
  59. Sarkar, 2014, Radiation-induced opticochiasmatic glioblastoma multiforme following conventional radiotherapy for Cushing's disease, Br J Neurosurg, 28, 510, 10.3109/02688697.2013.841850 · doi:10.3109/02688697.2013.841850
  60. Larson, 1993, The radiobiology of radiosurgery, Int J Radiat Oncol Biol Phys, 25, 557, 10.1016/0360-3016(93)90080-F · doi:10.1016/0360-3016(93)90080-f
  61. Croughs, 1971, Immediate effect of unilateral adrenalectomy followed by external pituitary irradiation on cortisol secretion rate in subjects suffering from pituitary dependent Cushing's syndrome, J Clin Endocrinol Metab, 33, 912, 10.1210/jcem-33-6-912 · doi:10.1210/jcem-33-6-912
  62. Lamberts, 1977, Evaluation of a therapeutic regimen in Cushing's disease. The predictability of the result of unilateral adrenalectomy followed by external pituitary irradiation, Acta Endocrinol (Copenh), 86, 146, 10.1530/acta.0.0860146 · doi:10.1530/acta.0.0860146
  63. Landau, 1978, Unilateral adrenalectomy and pituitary irradiation in the treatment of ACTH-dependent Cushing's disease in children and adolescents, Clin Endocrinol (Oxf), 9, 221, 10.1111/j.1365-2265.1978.tb02203.x · doi:10.1111/j.1365-2265.1978.tb02203.x
  64. Ernest, 1972, Adrenalectomy in Cushing's disease. A long-term follow-up, Acta Endocrinol Suppl (Copenh), 160, 3
  65. Tomita, 1981, Follow-up study on treatment in 27 patients with Cushing's disease: adrenalectomy, transsphenoidal adenomectomy and medical treatment, Endocrinol Jpn, 28, 197, 10.1507/endocrj1954.28.197 · doi:10.1507/endocrj1954.28.197
  66. Kelly, 1983, Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients, Q J Med, 52, 224
  67. Bax, 1996, Laparoscopic bilateral adrenalectomy following failed hypophysectomy, Surg Endosc, 10, 1150, 10.1007/s004649900268 · doi:10.1007/s004649900268
  68. Chapuis, 1997, Bilateral laparoscopic adrenalectomy for Cushing's disease, Br J Surg, 84, 1009, 10.1002/bjs.1800840731 · doi:10.1002/bjs.1800840731
  69. Acosta, 1999, Laparoscopic versus open adrenalectomy in Cushing's syndrome and disease, Surgery, 126, 1111, 10.1067/msy.2099.102423 · doi:10.1067/msy.2099.102423
  70. Mikhail, 2006, Open versus laparoscopic simultaneous bilateral adrenalectomy, Urology, 67, 693, 10.1016/j.urology.2005.10.037 · doi:10.1016/j.urology.2005.10.037
  71. Bulus, 2013, Comparison of laparoscopic and open adrenalectomy, Acta Chir Belg, 113, 203, 10.1080/00015458.2013.11680912 · doi:10.1080/00015458.2013.11680912
  72. Munir, 2007, Nelson's syndrome, Arq Bras Endocrinol Metabol, 51, 1392, 10.1590/S0004-27302007000800026 · doi:10.1590/s0004-27302007000800026
  73. Kasperlik-Załuska, 2006, Nelson's syndrome – 46 years later: clinical experience with 37 patients, Zentralbl Neurochir, 67, 14, 10.1055/s-2006-921430 · doi:10.1055/s-2006-921430
  74. Xing, 2002, Microsurgical treatment of Nelson's syndrome, Chin Med J Engl, 115, 1150
  75. Kemink, 2001, Management of Nelson's syndrome: observations in fifteen patients, Clin Endocrinol (Oxf), 54, 45, 10.1046/j.1365-2265.2001.01187.x · doi:10.1046/j.1365-2265.2001.01187.x
  76. Wolffenbuttel, 1998, Beneficial gamma-knife radiosurgery in a patient with Nelson's syndrome, Clin Neurol Neurosurg, 100, 60, 10.1016/S0303-8467(97)00124-8 · doi:10.1016/s0303-8467(97)00124-8
  77. Moore, 1976, Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation, Ann Intern Med, 85, 731, 10.7326/0003-4819-85-6-731 · doi:10.7326/0003-4819-85-6-731
  78. Vik-Mo, 2009, Gamma knife stereotactic radiosurgery of Nelson syndrome, Eur J Endocrinol, 160, 143, 10.1530/EJE-08-0687 · doi:10.1530/eje-08-0687
  79. Gil-Cárdenas, 2007, Nelson's syndrome after bilateral adrenalectomy for Cushing's disease, Surgery, 141, 147, 10.1016/j.surg.2006.12.003 · doi:10.1016/j.surg.2006.12.003
  80. Kreutzer, 2009, No effect of the PPAR-γ agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo, Clin Neuropathol, 28, 430
  81. Moyes, 2009, Treatment of Nelson's syndrome with temozolomide, Eur J Endocrinol, 160, 115, 10.1530/EJE-08-0557 · doi:10.1530/eje-08-0557
  82. Berselli, 1987, Effect of ketoconazole on CRH-induced ACTH and cortisol release in patients with Cushing's disease, Horm Metab Res Suppl, 16, 58
  83. Tabarin, 1990, Efficacy and long-term tolerance of ketoconazole in the treatment of Cushing's disease [in French], Ann Endocrinol (Paris), 51, 27
  84. Manavela, 2001, The association of Cushing's disease and primary empty sella turcica, Pituitary, 4, 145, 10.1023/A:1015310806063 · doi:10.1023/a:1015310806063
  85. Kazy, 2005, Population-based case-control study of oral ketoconazole treatment for birth outcomes, Congenit Anom (Kyoto), 45, 5, 10.1111/j.1741-4520.2005.00053.x · doi:10.1111/j.1741-4520.2005.00053.x
  86. Chart, 1958, New amphenone analogs as adrenocortical inhibitors, Experientia, 14, 151, 10.1007/BF02157133 · doi:10.1007/bf02157133
  87. Dewis, 1983, Experience with trilostane in the treatment of Cushing's syndrome, Clin Endocrinol (Oxf), 18, 533, 10.1111/j.1365-2265.1983.tb00590.x · doi:10.1111/j.1365-2265.1983.tb00590.x
  88. Doenicke, 1994, A comparison of two formulations for etomidate, 2-hydroxypropyl-β-cyclodextrin (HPCD) and propylene glycol, Anesth Analg, 79, 933, 10.1213/00000539-199411000-00020 · doi:10.1213/00000539-199411000-00020
  89. Zacharias, 1979, Venous sequelae following etomidate, Br J Anaesth, 51, 779, 10.1093/bja/51.8.779 · doi:10.1093/bja/51.8.779
  90. Doenicke, 1997, Haemolysis after etomidate: comparison of propylene glycol and lipid formulations, Br J Anaesth, 79, 386, 10.1093/bja/79.3.386 · doi:10.1093/bja/79.3.386
  91. Yorgin, 1997, Propylene glycol-induced proximal renal tubular cell injury, Am J Kidney Dis, 30, 134, 10.1016/S0272-6386(97)90577-1 · doi:10.1016/s0272-6386(97)90577-1
  92. Hart, 1971, Studies on the site of action of o,p'-DDD in the dog adrenal cortex. 1. Inhibition of ACTH-mediated pregnenolone synthesis, Steroids, 17, 559, 10.1016/S0039-128X(71)80157-5 · doi:10.1016/s0039-128x(71)80157-5
  93. Southren, 1961, Effect of o,p'DDD in a patient with Cushing's syndrome, J Clin Endocrinol Metab, 21, 201, 10.1210/jcem-21-2-201 · doi:10.1210/jcem-21-2-201
  94. Dickerman, 1979, Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient, Isr J Med Sci, 15, 455
  95. Takamatsu, 1981, Does mitotane reduce endogenous ACTH secretion?, N Engl J Med, 305, 957, 10.1056/NEJM198110153051617 · doi:10.1056/nejm198110153051617
  96. Suda, 1983, Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease, J Clin Endocrinol Metab, 56, 1094, 10.1210/jcem-56-6-1094 · doi:10.1210/jcem-56-6-1094
  97. Plonk, 1976, Modification of adrenal function by the anti-serotonin agent cyproheptadine, J Clin Endocrinol Metab, 42, 291, 10.1210/jcem-42-2-291 · doi:10.1210/jcem-42-2-291
  98. Kriegert, 1976, Letter: cyproheptadine for pituitary disorders, N Engl J Med, 295, 394, 10.1056/NEJM197608122950715 · doi:10.1056/nejm197608122950715
  99. Ambrosi, 1979, Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome, Horm Metab Res, 11, 318, 10.1055/s-0028-1095778 · doi:10.1055/s-0028-1095778
  100. Tyrrell, 1976, More on cyproheptadine, N Engl J Med, 295, 1137, 10.1056/NEJM197611112952017 · doi:10.1056/nejm197611112952017
  101. Copinschi, 1977, Lack of effect of cyproheptadine in Cushing's disease and in Nelson's syndrome, Acta Endocrinol (Copenh), 312
  102. Koppeschaar, 1983, Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease, Acta Endocrinol (Copenh), 104, 160, 10.1530/acta.0.1040160 · doi:10.1530/acta.0.1040160
  103. Tucci, 1989, Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation, J Endocrinol Invest, 12, 197, 10.1007/BF03349961 · doi:10.1007/bf03349961
  104. Hsu, 1981, Cyproheptadine in the control of Cushing's disease, Johns Hopkins Med J, 149, 77
  105. Barnes, 1977, Cushing's disease: successful treatment with cyproheptadine, Lancet, 1, 1148, 10.1016/S0140-6736(77)92402-3 · doi:10.1016/s0140-6736(77)92402-3
  106. Ooi, 1987, Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma, J Endocrinol Invest, 10, 107, 10.1007/BF03347166 · doi:10.1007/bf03347166
  107. Middler, 1976, Letter: cyproheptadine for pituitary disorders, N Engl J Med, 295, 394, 10.1056/NEJM197608122950715 · doi:10.1056/nejm197608122950715
  108. Ferrari, 1977, More on cyproheptadine in Cushing's disease, N Engl J Med, 296, 576, 10.1056/NEJM197703102961022 · doi:10.1056/nejm197703102961022
  109. Grant, 1979, Cushing's disease presenting with growth failure: clinical remission during cyproheptadine therapy, Arch Dis Child, 54, 466, 10.1136/adc.54.6.466 · doi:10.1136/adc.54.6.466
  110. Pearce, 1977, Treatment of Cushing's disease with cyproheptadine, Lancet, 1, 1368, 10.1016/S0140-6736(77)92585-5 · doi:10.1016/s0140-6736(77)92585-5
  111. Allgrove, 1977, Cushing's disease: failure of treatment with cyproheptadine, Br Med J, 1, 686, 10.1136/bmj.1.6062.686-a · doi:10.1136/bmj.1.6062.686-a
  112. D'Ercole, 1977, Treatment of Cushing disease in childhood with cyproheptadine, J Pediatr, 90, 834, 10.1016/S0022-3476(77)81265-1 · doi:10.1016/s0022-3476(77)81265-1
  113. Kritzler, 1983, Sodium valproate and corticotropin suppression in the child treated for seizures, J Pediatr, 102, 142, 10.1016/S0022-3476(83)80313-8 · doi:10.1016/s0022-3476(83)80313-8
  114. Koppeschaar, 1982, Sodium valproate and heterogeneity of pituitary dependent Cushing's syndrome, Lancet, 1, 1253, 10.1016/S0140-6736(82)92383-2 · doi:10.1016/s0140-6736(82)92383-2
  115. Koppeschaar, 1984, Successful treatment with sodium valproate of a patient with Cushing's disease and gross enlargement of the pituitary, Acta Endocrinol (Copenh), 107, 471, 10.1530/acta.0.1070471 · doi:10.1530/acta.0.1070471
  116. Cavagnini, 1984, Sodium valproate in Cushing's disease, Lancet, 2, 162, 10.1016/S0140-6736(84)91074-2 · doi:10.1016/s0140-6736(84)91074-2
  117. Ambrosi, 1983, Effects of sodium-valproate administration on plasma ACTH levels in patients with ACTH hypersecretion, J Endocrinol Invest, 6, 305, 10.1007/BF03347595 · doi:10.1007/bf03347595
  118. Reincke, 1988, The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease, Klin Wochenschr, 66, 686, 10.1007/BF01726927 · doi:10.1007/bf01726927
  119. Loli, 1984, Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion, J Endocrinol Invest, 7, 93, 10.1007/BF03348396 · doi:10.1007/bf03348396
  120. Allolio, 1982, Valproate in Cushing's syndrome, Lancet, 1, 171, 10.1016/S0140-6736(82)90422-6 · doi:10.1016/s0140-6736(82)90422-6
  121. Koppeschaar, 1986, Response to neurotransmitter modulating drugs in patients with Cushing's disease, Clin Endocrinol (Oxf), 25, 661, 10.1111/j.1365-2265.1986.tb03621.x · doi:10.1111/j.1365-2265.1986.tb03621.x
  122. Beckers, 1990, Cyclical Cushing's disease and its successful control under sodium valproate, J Endocrinol Invest, 13, 923, 10.1007/BF03349657 · doi:10.1007/bf03349657
  123. Nussey, 1988, The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome, Clin Endocrinol (Oxf), 28, 373, 10.1111/j.1365-2265.1988.tb03668.x · doi:10.1111/j.1365-2265.1988.tb03668.x
  124. Ferone, 2007, Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas, Eur J Endocrinol, 156, S37, 10.1530/eje.1.02351 · doi:10.1530/eje.1.02351
  125. Nobels, 2000, Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma, Eur J Endocrinol, 143, 615, 10.1530/eje.0.1430615 · doi:10.1530/eje.0.1430615
  126. Greenman, 2005, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth, Clin Endocrinol (Oxf), 63, 39, 10.1111/j.1365-2265.2005.02295.x · doi:10.1111/j.1365-2265.2005.02295.x
  127. Pirker, 1996, Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT, J Nucl Med, 37, 1931
  128. Adams, 1981, Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism, Clin Endocrinol (Oxf), 15, 479, 10.1111/j.1365-2265.1981.tb00691.x · doi:10.1111/j.1365-2265.1981.tb00691.x
  129. Yin, 1994, Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine, FEBS Lett, 339, 73, 10.1016/0014-5793(94)80387-0 · doi:10.1016/0014-5793(94)80387-0
  130. Lamberts, 1977, The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy, Clin Endocrinol (Oxf), 7, 185, 10.1111/j.1365-2265.1977.tb01314.x · doi:10.1111/j.1365-2265.1977.tb01314.x
  131. Adachi, 1996, Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine, Intern Med, 35, 207, 10.2169/internalmedicine.35.207 · doi:10.2169/internalmedicine.35.207
  132. McNicol, 1986, A study of corticotroph adenomas in Cushing's disease: no evidence of intermediate lobe origin, Clin Endocrinol (Oxf), 24, 715, 10.1111/j.1365-2265.1986.tb01668.x · doi:10.1111/j.1365-2265.1986.tb01668.x
  133. Meij, 2000, Double pituitary lesions in three patients with Cushing's disease, Pituitary, 3, 159, 10.1023/A:1011499609096 · doi:10.1023/a:1011499609096
  134. Nielsen, 2001, Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo, J Endocrinol Invest, 24, 430, 10.1007/BF03351043 · doi:10.1007/bf03351043
  135. Pivonello, 2003, Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors, J Endocrinol Invest, 26, 82
  136. Invitti, 1991, Effect of sandostatin on CRF-stimulated secretion of ACTH, β-lipotropin and β-endorphin, Horm Metab Res, 23, 233, 10.1055/s-2007-1003660 · doi:10.1055/s-2007-1003660
  137. Julesz, 1980, Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease, Endokrinologie, 76, 68
  138. Kraus, 1999, Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids, FEBS Lett, 459, 200, 10.1016/S0014-5793(99)01236-3 · doi:10.1016/s0014-5793(99)01236-3
  139. Ruan, 2006, SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?, Mol Endocrinol, 20, 426, 10.1210/me.2005-0283 · doi:10.1210/me.2005-0283
  140. Lacroix, 2012, Medical treatment of Cushing's disease with pasireotide, Eur J Endocrinol, 8, 99, 10.17925/EE.2012.08.02.99 · doi:10.17925/ee.2012.08.02.99
  141. Cukier, 2009, Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease, Clin Endocrinol (Oxf), 71, 305, 10.1111/j.1365-2265.2008.03486.x · doi:10.1111/j.1365-2265.2008.03486.x
  142. Culler, 2011, Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors, Horm Metab Res, 43, 854, 10.1055/s-0031-1287769 · doi:10.1055/s-0031-1287769
  143. Colao, 2010, Pituitary carcinomas, Front Horm Res, 38, 94, 10.1159/000318499 · doi:10.1159/000318499

Cited by

See all 465

Metadata

Authors
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A.
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
2015-08-01
Volume
36
Issue
4
Pages
385-486
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/er.2013-1048
OpenAlex
W1910274646
Cited by
465
References
641
FWCI
27.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Treatment of Cushing's Disease. https://app.cochat.ai/papers/10.1210/er.2013-1048
The paper
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015). The Treatment of Cushing's Disease. Endocrine Reviews. https://doi.org/10.1210/er.2013-1048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.